About: Drug Delivery–mediated Control of RNA Immunostimulation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Drug Delivery–mediated Control of RNA Immunostimulation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Drug Delivery–mediated Control of RNA Immunostimulation
Creator	Novobrantseva, Tatiana Chen, Jianzhu Chen, Steve C-Y Goldberg, Michael Kim, Phillip Langer, Robert Lu, James Sherman, Jennifer Shulga-Morskaya, Svetlana Sprague, Andrew Anderson, Daniel De Fougerolles, Antonin Nguyen, David
Source	Elsevier; Medline; PMC
abstract	RNA interference (RNAi) has generated significant interest as a strategy to suppress viral infection, but in some cases antiviral activity of unmodified short-interfering RNA (siRNA) has been attributed to activation of innate immune responses. We hypothesized that immunostimulation by unmodified siRNA could mediate both RNAi as well as innate immune stimulation depending on the mode of drug delivery. We investigated the potential of immunostimulatory RNAs (isRNAs) to suppress influenza A virus in vivo in the mouse lung. Lipidoid 98N12-5(1) formulated with unmodified siRNA targeting the influenza nucleoprotein gene exhibited antiviral activity. Formulations were optimized to increase antiviral activity, but the antiviral activity of lipidoid-delivered siRNA did not depend on sequence homology to the influenza genome as siRNA directed against unrelated targets also suppressed influenza replication in vivo. This activity was primarily attributed to enhancement of innate immune stimulation by lipidoid-mediated delivery, which indicates increased toll-like receptor (TLR) activation by siRNA. Certain chemical modifications to the siRNA backbone, which block TLR7/8 activation but retain in vitro RNAi activity, prevented siRNA-mediated antiviral activity despite enhanced lipidoid-mediated delivery. Here, we demonstrate that innate immune activation caused by unmodified siRNA can have therapeutically relevant effects, and that these non-RNAi effects can be controlled through chemical modifications and drug delivery.
has issue date	2009-09-01(xsd:dateTime)
bibo:doi	10.1038/mt.2009.147
bibo:pmid	19584813
has license	hybrid-oa
sha1sum (hex)	d06e52597d4ab4906bad8ca520341ff7d6edf885
schema:url	https://doi.org/10.1038/mt.2009.147
resource representing a document's title	Drug Delivery–mediated Control of RNA Immunostimulation
has PubMed Central identifier	PMC2835254
has PubMed identifier	19584813
schema:publication	Molecular Therapy
resource representing a document's body	covid:d06e52597d4ab4906bad8ca520341ff7d6edf885#body_text
is schema:about of	named entity 'CONTROL' named entity 'DELIVERY' named entity 'MEDIATED' named entity 'RNA' named entity 'DRUG DELIVERY' named entity 'IMMUNOSTIMULATION' named entity 'mmol/l' named entity 'housekeeping gene' named entity 'delivery systems' named entity 'antiviral activity' named entity 'anti-influenza' named entity 'TLR3' named entity 'RNAi' named entity 'mice' named entity 'uridine' named entity 'siRNA' named entity 'flu' named entity 'IFN' named entity 'branched DNA assay' named entity 'siRNA' named entity 'immunostimulation' named entity 'RNAi' named entity 'TLR8' named entity 'bDNA' named entity 'homogenized' named entity 'RNAi' named entity 'mice' named entity 'IFN' named entity 'influenza infection' named entity 'prophylactic' named entity 'genome' named entity 'siRNA' named entity 'mRNA' named entity 'base sequence' named entity 'gene' named entity 'RNA interference' named entity 'antiviral activity' named entity 'late endosome' named entity 'PBS' named entity 'Fluorescence' named entity 'RNAi' named entity 'cholesterol' named entity 'cleavage site' named entity 'Indianapolis' named entity 'dsRNA' named entity 'Madin-Darby canine kidney cells' named entity 'nanoparticles' named entity 'hepatitis' named entity 'liver' named entity 'siRNA' named entity 'siNP' named entity 'liquid nitrogen' named entity 'siRNA' named entity 'streptomycin' named entity 'serum' named entity 'RNA' named entity 'siRNAs' named entity 'HEPES' named entity 'mice' named entity 'virus' named entity 'nmol/l' named entity 'mRNA' named entity 'xylazine' named entity 'RNAi' named entity 'transfection' named entity 'siRNAs' named entity 'antiviral activity' named entity 'TLR' named entity 'RNA'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software